FindTrial
Sign In

Positron Emission Mammography

PROCEDURE5 trials

Sponsors

Naviscan PET Systems, Boston Medical Center, University of Chicago, Sidney Kimmel Cancer Center at Thomas Jefferson University, National Cancer Institute (NCI)

Conditions

Anaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-PositiveApocrine CarcinomaBreast CancerBreast CarcinomaCarcinoma Arising From CylindromaCarcinoma Arising From SpiradenomaDigital Papillary Adenocarcinoma

Phase 2

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Active, not recruitingNCT02978625
National Cancer Institute (NCI)Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma +36
Start: 2017-09-27End: 2027-09-01Target: 68Updated: 2026-04-03

Phase 4

Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer
NCT00484614
Naviscan PET SystemsBreast Cancer
Start: 2006-09-30End: 2009-03-31Updated: 2009-09-03

Unknown Phase

Positron Emission Mammography and Standard Mammography in Women at High Risk of Breast Cancer
CompletedNCT00896649
Boston Medical CenterBreast Cancer
Start: 2009-02-28End: 2017-01-31Updated: 2017-05-09
Staging of Axillary Lymph Nodes Using the PEM Flex Solo II Pet Scanner in Patients With Breast Cancer
CompletedNCT01011946
University of ChicagoBreast Cancer
Start: 2009-11-30End: 2012-05-31Updated: 2015-07-09
Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer
TerminatedNCT02810873
Sidney Kimmel Cancer Center at Thomas Jefferson UniversityBreast Carcinoma
Start: 2008-09-30End: 2012-07-31Updated: 2025-05-04

Related Papers

Onkolytische Viren zur Verstärkung der PD‐1‐Hemmung bei metastasierendem kutanem Plattenepithelkarzinom
JDDG Journal der Deutschen Dermatologischen Gesellschaft2024-07-01
A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).
Journal of Clinical Oncology2018-02-107 citations